Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
The price of Tscan Therapeutics Inc (NASDAQ: TCRX) closed at $1.4 in the last session, down -5.41% from day before closing price of $1.48. In other words, the price has decreased by -$5.41 from its previous closing price. On the day, 5.39 million shares were traded. TCRX stock price reached its highest trading level at $1.53 during the session, while it also had its lowest trading level at $1.4.
Ratios:
We take a closer look at TCRX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 8.55 and its Current Ratio is at 8.55. In the meantime, Its Debt-to-Equity ratio is 0.46 whereas as Long-Term Debt/Eq ratio is at 0.44.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BTIG Research on May 16, 2024, initiated with a Buy rating and assigned the stock a target price of $12.
On May 13, 2024, Needham started tracking the stock assigning a Buy rating and target price of $11.
On June 22, 2023, Wedbush started tracking the stock assigning a Outperform rating and target price of $8.Wedbush initiated its Outperform rating on June 22, 2023, with a $8 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on May 19 ’25 when Lynx1 Capital Management LP bought 1,388,794 shares for $1.20 per share. The transaction valued at 1,666,553 led to the insider holds 6,746,141 shares of the business.
Lynx1 Capital Management LP bought 1,200,000 shares of TCRX for $1,440,000 on May 20 ’25. The 10% Owner now owns 7,946,141 shares after completing the transaction at $1.20 per share. On Dec 13 ’24, another insider, Lynx1 Capital Management LP, who serves as the 10% Owner of the company, bought 100,000 shares for $2.90 each. As a result, the insider paid 290,140 and bolstered with 5,357,347 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TCRX now has a Market Capitalization of 79226840 and an Enterprise Value of -75425120. For the stock, the TTM Price-to-Sale (P/S) ratio is 17.93 while its Price-to-Book (P/B) ratio in mrq is 0.38. Its current Enterprise Value per Revenue stands at -17.061 whereas that against EBITDA is 0.554.
Stock Price History:
The Beta on a monthly basis for TCRX is 0.98, which has changed by -0.7639123 over the last 52 weeks, in comparison to a change of 0.12748289 over the same period for the S&P500. Over the past 52 weeks, TCRX has reached a high of $7.89, while it has fallen to a 52-week low of $1.02. The 50-Day Moving Average of the stock is -6.31%, while the 200-Day Moving Average is calculated to be -52.47%.
Shares Statistics:
According to the various share statistics, TCRX traded on average about 571.16K shares per day over the past 3-months and 914980 shares per day over the past 10 days. A total of 52.31M shares are outstanding, with a floating share count of 43.83M. Insiders hold about 22.56% of the company’s shares, while institutions hold 71.46% stake in the company. Shares short for TCRX as of 1749772800 were 2268054 with a Short Ratio of 3.97, compared to 1747267200 on 2303027. Therefore, it implies a Short% of Shares Outstanding of 2268054 and a Short% of Float of 4.8800003.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
